SNSS Stock News 4.76 05/13/2014 17:37:27 Sunesis Pharmaceuticals

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Sunesis Pharmaceuticals (SNSS) 4.76 $SNSS

Biotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, Merrimack
at The Street - Fri May 09, 5:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Is Sunesis Pharmaceuticals Poised for a Breakout?
George Budwell, The Motley Fool - Motley Fool - Thu May 08, 5:51AM CDT
So far this year, we've seen a handful of developmental-stage oncology companies report positive late-stage data for their therapeutic candidates, resulting in major rallies in their respective share prices. For example, Endocyte , InterMune , and...

Sunesis Pharmaceuticals Reports First Quarter 2014 Financial Results and Recent Highlights
GlobeNewswire - Wed May 07, 6:00AM CDT
Receives FDA Acceptance for Trademark Name Qinprezo(TM)

Sunesis to Host Conference Call on May 7th to Discuss First Quarter 2014 Financial Results and Recent Highlights
GlobeNewswire - Wed Apr 30, 6:16AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Wednesday, May 7, 2014 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the first quarter ended March 31, 2014.

3 Ways Ariad Pharmaceuticals Could Mount a Comeback
George Budwell, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
Ariad Pharmaceuticals  has the dubious honor of being one of the worst-performing stocks in the past year, dropping over 60% in that time frame. As a brief refresher, shares dropped following a clinical hold on the company's only commercial product...

Sunesis Announces MD Anderson Sponsored Study of Vosaroxin in AML and High-Risk MDS Poster to be Presented at ASCO 2014
GlobeNewswire - Tue Apr 22, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that updated data from the ongoing Phase 1b/2 University of Texas MD Anderson Cancer Center-sponsored study of vosaroxin in combination with decitabine in older patients with previously untreated acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) will be presented at the 2014 American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago, Illinois.

2 Biotech Stocks to Watch: Merrimack Pharmaceuticals and Sunesis Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Thu Apr 10, 5:30PM CDT
Although 2014 has gotten off to a rocky start for biotechs, a fair number of companies have exploded higher after reporting positive clinical trial data. For example, Endocyte doubled in a day after unveiling positive data for its experimental...

Ambit's Oncology Drug in Phase III - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 3:55PM CDT
Ambit Biosciences commenced a phase III study (QUANTUM-R) on its lead oncology candidate, quizartinib for acute myeloid leukemia (AML).

Sunesis Announces Presentation of Positive Results From Ongoing MD Anderson-Sponsored Trial of Vosaroxin in AML and High-Risk MDS
GlobeNewswire - Tue Apr 08, 8:39AM CDT
Data Presented at AACR 2014 Annual Meeting

Is Now the Time to Invest in Agios Pharmaceuticals, Inc?
George Budwell, The Motley Fool - Motley Fool - Mon Apr 07, 10:17AM CDT
Shares of Agios Pharmaceuticals spiked over 20% this morning after the company announced that its early stage blood cancer drug, AG-221, is showing unexpectedly strong efficacy signals. Specifically, six of the seven evaluable patients exhibited...

Sunesis Announces MD Anderson Sponsored Trial of Vosaroxin in AML and High-Risk MDS Poster to be Presented at AACR 2014
GlobeNewswire - Wed Apr 02, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that updated data from the ongoing Phase 1b/2 University of Texas MD Anderson Cancer Center-sponsored trial of vosaroxin in combination with decitabine in older patients with previously untreated acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) will be presented at the American Association for Cancer Research Annual Meeting 2014 (AACR) in San Diego, California.

Nasdaq stocks posting largest percentage decreases
AP - Fri Mar 28, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:

Appointments, Financial Reports, and FDA Approvals - Analyst Notes on Hospira, Karyopharm, Revance, Pluristem, and Sunesis
PR Newswire - Tue Mar 11, 8:19AM CDT
Today, Analysts Review released its analysts' notes regarding Hospira Inc. (NYSE: HSP), Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), Revance Therapeutics, Inc. (NASDAQ: RVNC), Pluristem Therapeutics, Inc. (NASDAQ: PSTI), and Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights
GlobeNewswire - Thu Mar 06, 6:09AM CST
Phase 1b/2 Data From MD Anderson Sponsored Study of Vosaroxin in AML and

Sunesis (SNSS) Jumps: Stock Moves 6.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 8:25AM CST
Sunesis was a big mover last session, as the company saw its shares rise nearly 7% on the day.

Sunesis to Present at Upcoming Investor Conferences
GlobeNewswire - Fri Feb 28, 7:18AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer and President of Sunesis, will present at two upcoming investor conferences;

Sunesis to Host Conference Call on March 6th to Discuss Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights
GlobeNewswire - Fri Feb 28, 7:18AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Thursday, March 6, 2014 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter and year ended December 31, 2013.

Sunesis Announces Pricing of a $43.0 Million Public Offering of Common Stock and Warrants
GlobeNewswire - Thu Feb 27, 8:53AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the pricing of an underwritten public offering of 4,650,000 shares of common stock together with two warrants to purchase one share of the company's common stock. The public offering price of each share of common stock and two accompanying warrants was $9.25, resulting in gross proceeds to the company of $43.0 million. Net proceeds are expected to be approximately $40.0 million, after deducting the underwriting discount and estimated offering expenses payable by Sunesis. If exercised in full, the warrants could result in additional net financing proceeds to Sunesis of $95.3 million. The offering is expected to close on or about March 4, 2014, subject to customary closing conditions.

Sunesis Announces Proposed Public Offering of Common Stock and Warrants
GlobeNewswire - Wed Feb 26, 3:14PM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 55

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
Voranigo Follow-Up Deepens the Glioma Care Debate Today

Updated Category News Views 44

Brain-tumor progress rarely arrives with a clean victory lap, but the longer INDIGO readout gives clinicians and sector watchers something sturdier than a one-time headline. Servier presented extended Phase 3 results for VORANIGO, or vorasidenib, at the Society for Neuro-Oncology meeting in Philadelphia on November 14 and 15, 2026. The central message is durable benefit...

Continue Reading
Kobo and CloudLibrary Make Library Ebooks Much Easier

Updated Category News Views 89

A tiny button can change whether a digital service gets used Borrowing an ebook ought not feel like assembling a radio in a dark garage, yet that is roughly where library reading has landed for plenty of people. OCLC's new CloudLibrary integration with Kobo strips out a particularly annoying step: U.S. and Canadian users can link accounts once, borrow a title, and have it...

Continue Reading
Wall Street Gains Hold Amid Volatility Drop

Updated Category News Views 66

A Week of Gains and Regulatory Moves Right out of the gate, it’s been a decent stretch for Wall Street. Weekly gains kept the party going, even as traders navigated the usual hurdles. Stocks finished the week with a solid performance—all the heavy hitters like Dow, S&P 500, Nasdaq, and Russell 2000 ended on a high note, waltzing uphill past where many imagined...

Continue Reading
InPHRED's Award Brings 1310 nm VCSELs Into Focus at IEEE

Updated Category News Views 45

A stubborn mirror problem just put InPHRED on the photonics map. InPHRED, founded in 2023, took the Best Technology award at the inaugural 2026 IEEE Photonics Conference Start-Up Competition, selected from seven finalists. That is a meaningful industry pat on the back, particularly because the company is aiming at a real engineering headache rather than waving around...

Continue Reading
Norris Lake's New Kayak Fleet Propels Tourism Efforts

Updated Category News Views 207

Norris Lake Doubles Down on Water Adventures The winds of change are paddling through Norris Dam State Park as they've launched a new fleet of shiny kayaks, hoping to lure more adventure seekers into the heart of Tennessee. These ain't just boats; they're part of a bigger play by local tourism honchos hungry to pump some adrenaline—and dollars—back into the area. A...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 154

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
GALLS Honors Service With Lexington Hall of Fame Wall

Updated Category News Views 56

A headquarters wall can say more about a company than another polished mission statement ever will. On November 17, 2026, GALLS® unveiled the National Law Enforcement Officer Hall of Fame Wall at its Lexington, Kentucky, corporate headquarters, displaying portraits of every past inductee into the National Law Enforcement Officer Hall of Fame. Recognition, made permanent...

Continue Reading
Sharon Stuart's Quest for Her Hidden Origins

Updated Category News Views 136

Delving Into Identity: A Personal Odyssey In a world where everyone seems to be searching for something, Sharon Stuart's quest is etched with the raw need to uncover her real origins. Abandoned as a newborn in the gritty streets of Oakland, she grew up grappling with looming questions about what made her who she is. Her journey is captured in her memoir, "Existing Without...

Continue Reading
RBI Prices $1 Billion of Secured Notes Due 2031, 2036

Updated Category News Views 135

A billion dollars of fresh paper just landed on Restaurant Brands International’s balance-sheet doorstep, and this one deserves more than the usual sleepy glance at a financing release. RBI has priced $500 million of 6.00% senior secured notes due 2031 and another $500 million of 6.40% senior secured notes due 2036. The expected closing date is November 24, 2026,...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionary Sports Bag Design: Functionality Redefined

Updated Category News Views 206

Alright, let’s slice into this sports bag buzz. We’re talking about a fresh entry in the accessories game—one that aims to flip traditional bags on their heads. This isn’t just any bag; it’s designed with dual compartments. Picture this: you’ve got your gear separated from your clothes or other essentials. Smart move, right? It screams organization, which is...

Continue Reading
Packaging Corporation of America: A Bright Future Ahead

Updated Category News Views 212

Positive Outlook for Packaging Corporation of America Jefferies analysts recently upgraded Packaging Corporation of America (NYSE: PKG) to a "buy" rating, indicating their confidence in the company’s potential to outperform its peers in the packaging industry. This endorsement is grounded in the expectation that the company will gain significantly over the next year....

Continue Reading
SKF Celebrates Sustainability Success with EcoVadis Award

Updated Category News Views 190

SKFs Recognition in Sustainability Efforts SKF has been awarded a prestigious Platinum Medal by EcoVadis, a well-regarded provider of sustainability ratings, marking the fifth consecutive year this honor has been received. This notable recognition places SKF within the top 1% of over 130,000 global companies assessed for their commitment to sustainable business practices....

Continue Reading
Quorum Set to Unveil Third Quarter 2025 Financial Insights

Updated Category News Views 188

Quorum Information Technologies Inc. Announces Q3 2025 Results Quorum Information Technologies Inc. (TSXV: QIS) is set to announce its earnings for the third quarter of 2025 after the market closes on a Wednesday in November. This North American SaaS company specializes in solutions for automotive dealerships and Original Equipment Manufacturers (OEMs), providing vital...

Continue Reading
Edible Garden Gains USDA Certification Assistance Amid Growth

Updated Category News Views 224

Edible Garden Receives USDA Grants for Organic Certification Edible Garden AG Incorporated (NASDAQ:EDBL, EDBLW) has made an impactful step forward by securing grants from the USDA Organic Certification Program. This funding is managed by the Farm Service Agency and is intended to support organic producers in their journey to gain and maintain organic certification. This...

Continue Reading